Camrelizumab + Apatinib
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intrahepatic Cholangiocarcinoma
Conditions
Intrahepatic Cholangiocarcinoma
Trial Timeline
Aug 1, 2020 → Jul 1, 2025
NCT ID
NCT04454905About Camrelizumab + Apatinib
Camrelizumab + Apatinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Intrahepatic Cholangiocarcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04454905. Target conditions include Intrahepatic Cholangiocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04454905 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Intrahepatic Cholangiocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Apatinib and Adebrelimab in Combination With chemotherapy | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Durvalumab + SNDX-6352 | AstraZeneca | Phase 2 | 52 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| Pemigatinib + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Durvalumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 52 |
| Pemigatinib | Incyte | Phase 2 | 49 |
| A4250 (odevixibat) | Ipsen | Phase 3 | 74 |
| Odevixibat | Ipsen | Pre-clinical | 20 |
| CGT4859 | Cogent Biosciences | Phase 1/2 | 38 |
| LUM001 (Maralixibat) | Mirum Pharmaceuticals | Phase 2 | 49 |
| Maralixibat | Mirum Pharmaceuticals | Phase 3 | 74 |
| Maralixibat | Mirum Pharmaceuticals | Phase 2 | 49 |
| Maralixibat | Mirum Pharmaceuticals | Phase 2 | 49 |
| Volixibat + Placebo | Mirum Pharmaceuticals | Phase 2 | 49 |
| Maralixibat | Mirum Pharmaceuticals | Phase 3 | 74 |
| Maralixibat + Placebo | Mirum Pharmaceuticals | Phase 3 | 74 |
| HMPL-453 + Rabeprazole | HUTCHMED | Phase 1 | 28 |